We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lentivirus Bioprocessing Kit to Support the Cell and Gene Therapy Market
Product News

Lentivirus Bioprocessing Kit to Support the Cell and Gene Therapy Market

Lentivirus Bioprocessing Kit to Support the Cell and Gene Therapy Market
Product News

Lentivirus Bioprocessing Kit to Support the Cell and Gene Therapy Market


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Lentivirus Bioprocessing Kit to Support the Cell and Gene Therapy Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gyros Protein Technologies AB, a developer of automated nanoliter-scale immunoassays and provider of peptide synthesizers and reagents, has announced the introduction of Gyrolab® p24 Kit, for lentivirus titer determination in lentivirus vector manufacturing. The new Gyrolab p24 Kit adds to the Company’s wide range of ready-to-use kits and Gyrolab Bioaffy CDs which are used by scientists and bioengineers in the rapidly growing cell and gene therapy market, where lentivirus vectors are commonly used to transport therapeutic genes.

Gyrolab p24 Kit offers high throughput and automated analyses, producing results 24 times faster than ELISA, to accelerate lentivirus bioprocess workflows and reduce time to market. The kit also enables high-quality data to be generated from small sample volumes, requiring 10 times less sample compared to ELISA. Additionally, minimal matrix interference reduces the need for dilution, increasing sensitivity and accuracy.

Kyriacos Mitrophanous PhD, CSO, Oxford Biomedica, commented: “Efficient bioprocessing, bioanalytical development, and manufacture of lentivirus vectors is vital for the advancing field of cell and gene therapy, which is creating an array of potential new treatment options for patients. A recent report highlighted that there are currently 289 novel cell and gene therapies in development for a variety of diseases and conditions, around 40% of which are targeting cancers. We’re pleased to see Gyros Protein Technologies developing vital products to support this field.” 


Advertisement